Donald Trump has backed psychedelic research, boosting funding and access to therapies using psilocybin and MDMA for depression, PTSD and anxiety. The move could accelerate clinical trials, reduce stigma and reshape mental health treatment. While promising, experts caution about risks, emphasising strict regulation and the need for further research before widespread adoption.